Oral and topical administration of a geranyl acetophenone attenuates DNCB-induced atopic dermatitis-like skin lesions in BALB/c mice.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Dermatitis, Atopic*/drug therapy ; Dermatitis, Atopic*/chemically induced ; Dermatitis, Atopic*/pathology ; Mice, Inbred BALB C* ; Dinitrochlorobenzene* ; Administration, Topical* ; Immunoglobulin E*/blood ; Skin*/drug effects ; Skin*/pathology ; Skin*/metabolism; Animals ; Administration, Oral ; Male ; Mice ; Disease Models, Animal ; Acetophenones/administration & dosage ; Acetophenones/pharmacology ; Acetophenones/therapeutic use ; Eosinophils/drug effects ; Interleukin-4/metabolism ; Mast Cells/drug effects

Atopic dermatitis (AD) is a chronic, allergic inflammatory skin disorder that lacks a definite cure. Using a mouse DNCB-induced AD-like skin lesions model, this study evaluated the potential therapeutic utility of tHGA as an oral and topical treatment for AD. Male BALB/c mice were sensitised and challenged with 1% and 0.5% DNCB on their shaved dorsal skin. Mice in the treatment group were administered tHGA (20, 40, and 80 mg/kg) orally three times per week for 2 weeks, or tHGA (0.2%, 1%, and 5%) topically once daily for 12 days. On day 34, the mice were euthanized, and blood and dorsal skin samples were obtained for analysis. All doses of orally and topically administered tHGA significantly improved scratching, epidermal thickness, blood eosinophilia and mast cell infiltration. There was a minor discrepancy between the two routes of administration, with orally treated tHGA showing significant reductions in Scoring of Atopic Dermatitis (SCORAD), tissue eosinophil infiltration, serum IgE and skin IL-4 levels with treatment of 40 and 80 mg/kg tHGA, whereas topically applied tHGA showed significant reductions in all dosages. These findings suggest that tHGA exhibited therapeutic potential for AD as both oral and topical treatment ameliorates AD-like symptoms in the murine model.
(© 2024. The Author(s).)

Erratum in: Sci Rep. 2024 Oct 1;14(1):22849. doi: 10.1038/s41598-024-73658-4. (PMID: 39354051)

Ständer, S. Atopic dermatitis. N. Engl. J. Med. 384, 1136–1143 (2021). (PMID: 3376120810.1056/NEJMra2023911)
Hadi, H. A. et al. The epidemiology and global burden of atopic dermatitis: A narrative review. Life Basel Switz. 11, 936 (2021).
Urban, K. et al. The global, regional, and national burden of atopic dermatitis in 195 countries and territories: An ecological study from the Global Burden of Disease Study 2017. JAAD Int. 2, 12–18 (2021). (PMID: 3440934710.1016/j.jdin.2020.10.002)
Pinart, M. et al. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: A population-based cohort study. Lancet Respir. Med. 2, 131–140 (2014). (PMID: 2450326810.1016/S2213-2600(13)70277-7)
Bantz, S. K., Zhu, Z. & Zheng, T. The atopic march: Progression from atopic dermatitis to allergic rhinitis and asthma. J. Clin. Cell Immunol. 5, 202 (2014). (PMID: 254194794240310)
Chow, S. et al. A clinician’s reference guide for the management of atopic dermatitis in Asians. Asia Pac. Allergy 8, e41. https://doi.org/10.5415/apallergy.2018.8.e41 (2018). (PMID: 10.5415/apallergy.2018.8.e41304024086209602)
Zuuren, E. J., Fedorowicz, Z., Christensen, R., Lavrijsen, A. P. & Arents, B. W. Emollients and moisturisers for eczema. Cochrane Database Syst. Rev. 2, CD12119. https://doi.org/10.1002/14651858.cd012119.pub2 (2017). (PMID: 10.1002/14651858.cd012119.pub2)
Drucker, A. M. et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br. J. Dermatol. 178, 768 (2018). (PMID: 28865094590139310.1111/bjd.15928)
Griffiths, C. E. M., van de Kerkhof, P. & Czarnecka-Operacz, M. Psoriasis and atopic dermatitis. Dermatol. Ther. 7, 31–41 (2017). (PMID: 10.1007/s13555-016-0167-9)
Choi, H. et al. Manifestation of atopic dermatitis-like skin in TNCB-induced NC/Nga mice is ameliorated by topical treatment of substance P, possibly through blockade of allergic inflammation. Exp. Dermatol. 27, 396–402 (2018). (PMID: 2883349910.1111/exd.13421)
Arkwright, P. D. et al. Management of difficult-to-treat atopic dermatitis. J. Allergy Clin. Immunol. Pract. 1, 142–151 (2013). (PMID: 2456545310.1016/j.jaip.2012.09.002)
Shaari, K. et al. Bioassay-guided identification of an anti-inflammatory prenylated acylphloroglucinol from Melicope ptelefolia and molecular insights into its interaction with 5-lipoxygenase. Bioorg. Med. Chem. 19, 6340–6347 (2011). (PMID: 2195873810.1016/j.bmc.2011.09.001)
Chan, Y. H. et al. Pharmacological properties of 2,4,6-trihydroxy-3-geranyl acetophenone and the underlying signaling pathways: Progress and prospects. Front. Pharmacol. 12, 736339. https://doi.org/10.3389/fphar.2021.736339 (2021). (PMID: 10.3389/fphar.2021.736339345317538438195)
Ismail, N. et al. A geranyl acetophenone targeting cysteinyl leukotriene synthesis prevents allergic airway inflammation in ovalbumin-sensitized mice. Toxicol. Appl. Pharmacol. 259, 257–262 (2012). (PMID: 2226634810.1016/j.taap.2012.01.003)
Tan, J. W. et al. Anti-allergic activity of 2,4,6-trihydroxy-3-geranylacetophenone (tHGA) via attenuation of IgE-mediated mast cell activation and inhibition of passive systemic anaphylaxis. Toxicol. Appl. Pharmacol. 319, 47–58 (2017). (PMID: 2816722310.1016/j.taap.2017.02.002)
Tan, J. W. et al. LAT is essential for the mast cell stabilising effect of tHGA in IgE-mediated mast cell activation. Biochem. Pharmacol. 144, 132–148 (2017). (PMID: 2881364510.1016/j.bcp.2017.08.010)
Keith, Y. H., Egawa, G., Honda, T. & Kabashima, K. Mast cells in type 2 skin inflammation: Maintenance and function. Eur. J. Immunol. 53, 2250359. https://doi.org/10.1002/eji.202250359 (2023). (PMID: 10.1002/eji.202250359)
Lee, Y. Z. et al. An orally active geranyl acetophenone attenuates airway remodeling in a murine model of chronic asthma. Eur. J. Pharmacol. 797, 53–64 (2017). (PMID: 2808991910.1016/j.ejphar.2017.01.011)
Myers, K. et al. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J. Dermatol. Treat. 34, 2215356. https://doi.org/10.1080/09546634.2023.2215356 (2023). (PMID: 10.1080/09546634.2023.2215356)
Megna, M. et al. Systemic treatment of adult atopic dermatitis: A review. Dermatol. Ther. 7, 1–23 (2016). (PMID: 10.1007/s13555-016-0170-1)
Lee, Y. Z. et al. Blockade of eosinophil-induced bronchial epithelial–mesenchymal transition with a geranyl acetophenone in a coculture model. Front. Pharmacol. 8, 837 (2017). (PMID: 29201006569632210.3389/fphar.2017.00837)
Yap, H. M. et al. The geranyl acetophenone tHGA attenuates human bronchial smooth muscle proliferation via inhibition of AKT phosphorylation. Sci. Rep. 8, 16640. https://doi.org/10.1038/s41598-018-34847-0 (2018). (PMID: 10.1038/s41598-018-34847-0304137536226528)
National Research Council. Guide for the Care and Use of Laboratory Animals, 8th edn. http://www.ncbi.nlm.nih.gov/books/NBK54050/ (National Academies Press, 2011).
Sert, N. P. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. BMC Vet. Res. 16, 242 (2020). (PMID: 10.1186/s12917-020-02451-y)
Jung, M. et al. Inhibitory effect of 5,6-dihydroergosteol-glucoside on atopic dermatitis-like skin lesions via suppression of NF-κB and STAT activation. J. Dermatol. Sci. 79, 252–261 (2015). (PMID: 2610003710.1016/j.jdermsci.2015.06.005)
Choi, Y. Y., Kim, M. H., Lee, H., Jo, S. Y. & Yang, W. M. (R)-(+)-pulegone suppresses allergic and inflammation responses on 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice model. J. Dermatol. Sci. 91, 292–300 (2018). (PMID: 2993389810.1016/j.jdermsci.2018.06.002)
Ku, J. M. et al. Effects of Angelicae dahuricae radix on 2, 4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in mice model. BMC Complement. Altern. Med. 17, 98 (2017). (PMID: 28173791529715210.1186/s12906-017-1584-8)
Arifin, W. N. & Zahiruddin, W. M. Sample size calculation in animal studies using resource equation approach. Malays. J. Med. Sci. 24, 101–105 (2017). (PMID: 29386977577282010.21315/mjms2017.24.5.11)
Lococo, D., Mora-Huertas, C. E., Fessi, H., Zaanoun, I. & Elaissari, A. Argan oil nanoemulsions as new hydrophobic drug-loaded delivery system for transdermal application. J. Biomed. Nanotechnol. 8, 843–848 (2012). (PMID: 2288875610.1166/jbn.2012.1445)
Hikita, I. et al. Characterization of dermatitis arising spontaneously in DS-Nh mice maintained under conventional conditions: Another possible model for atopic dermatitis. J. Dermatol. Sci. 30, 142–153 (2002). (PMID: 1241377010.1016/S0923-1811(02)00070-1)
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K. & Irvine, A. D. Atopic dermatitis. Nat. Rev. Dis. Primer 84, 1–20 (2018). (PMID: 10.1038/s41572-018-0001-z)
Silverberg, J. I. et al. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study. Br. J. Dermatol. 184, 888–895 (2021). (PMID: 3295939010.1111/bjd.19457)
De Vuyst, E., Salmon, M., Evrard, C., Lambert de Rouvroit, C. & Poumay, Y. Atopic dermatitis studies through in vitro models. Front. Med. 4, 119. https://doi.org/10.3389/fmed.2017.00119 (2017). (PMID: 10.3389/fmed.2017.00119)
Jin, H., He, R., Oyoshi, M. & Geha, R. S. Animal models of atopic dermatitis. J. Investig. Dermatol. 129, 31–40 (2009). (PMID: 1907898610.1038/jid.2008.106)
Grabbe, S. & Schwarz, T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol. Today 19, 37–44 (1998). (PMID: 946548710.1016/S0167-5699(97)01186-9)
Watanabe, H., Unger, M., Tuvel, B., Wang, B. & Sauder, D. N. Contact hypersensitivity: The mechanism of immune responses and T cell balance. J. Interferon Cytokine Res. Off J. Int. Soc. Interferon Cytokine Res. 22, 407–412 (2002). (PMID: 10.1089/10799900252952181)
Brandt, E. B. & Sivaprasad, U. Th2 cytokines and atopic dermatitis. J. Clin. Cell Immunol. 2, 110 (2011). (PMID: 21994899318950610.4172/2155-9899.1000110)
Chiricozzi, A., Maurelli, M., Peris, K. & Girolomoni, G. Targeting IL-4 for the treatment of atopic dermatitis. ImmunoTargets Ther. 9, 151–156 (2020). (PMID: 33062619753290710.2147/ITT.S260370)
Lee, G. R. & Flavell, R. A. Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int. Immunol. 16, 1155–1160 (2004). (PMID: 1522627110.1093/intimm/dxh117)
Spergel, J. M., Mizoguchi, E., Oettgen, H., Bhan, A. K. & Geha, R. S. Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J. Clin. Investig. 103, 1103–1111 (1999). (PMID: 1020716140827710.1172/JCI5669)
Radonjic-Hoesli, S., Brüggen, M.-C., Feldmeyer, L., Simon, H.-U. & Simon, D. Eosinophils in skin diseases. Semin. Immunopathol. 43, 393–409 (2021). (PMID: 34097126824174810.1007/s00281-021-00868-7)
Wu, T., Tang, L., Feng, Y., Jia, Y. & Li, F. Eosinophils and associated parameters in different types of skin diseases related to elevated eosinophil levels. Ann. Transl. Med. 10, 73 (2022). (PMID: 35282056884837110.21037/atm-22-99)
Simon, D., Braathen, L. R. & Simon, H.-U. Eosinophils and atopic dermatitis. Allergy 59, 561–570 (2004). (PMID: 1514743810.1111/j.1398-9995.2004.00476.x)
Galli, S. J., Maurer, M. & Lantz, C. S. Mast cells as sentinels of innate immunity. Curr. Opin. Immunol. 11, 53–59 (1999). (PMID: 1004753910.1016/S0952-7915(99)80010-7)
Kawakami, T., Ando, T., Kimura, M., Wilson, B. S. & Kawakami, Y. Mast cells in atopic dermatitis. Curr. Opin. Immunol. 21, 666–678 (2009). (PMID: 19828304283987910.1016/j.coi.2009.09.006)
Vaneckova, J. & Bukač, J. The severity of atopic dermatitis and the relation to the level of total IgE, onset of atopic dermatitis and family history about atopy. Food Agric. Immunol. 27, 734–741 (2016). (PMID: 10.1080/09540105.2016.1183598)
Vigo, P. G. et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J. Am. Acad. Dermatol. 55, 168–170 (2006). (PMID: 1678132010.1016/j.jaad.2005.12.045)
Finn, D. F. & Walsh, J. J. Twenty-first century mast cell stabilizers. Br. J. Pharmacol. 170, 23–37 (2013). (PMID: 23441583376484610.1111/bph.12138)
McGill, J. I. A review of the use of olopatadine in allergic conjunctivitis. Int. Ophthalmol. 25, 171–179 (2004). (PMID: 1584731710.1007/s10792-004-1818-x)
Robin, J. L., Seldin, D. C., Austen, K. F. & Lewis, R. A. Regulation of mediator release from mouse bone marrow-derived mast cells by glucocorticoids. J. Immunol. 135, 2719–2726 (1985). (PMID: 316194710.4049/jimmunol.135.4.2719)
Yamaguchi, M. et al. Regulation of mouse mast cell surface Fc epsilon RI expression by dexamethasone. Int. Immunol. 13, 843–851 (2001). (PMID: 1143141410.1093/intimm/13.7.843)
Bruley, D. F. & Bicher, H. I. Oxygen Transport to Tissue: Pharmacology, Mathematical Studies, and Neonatology (Springer, 1973). https://doi.org/10.1007/978-1-4684-5089-7 . (PMID: 10.1007/978-1-4684-5089-7)
Al-kaf, A. G. A. & Othman, A. M. A review on needle free injections. Univers. J. Pharm. Res. 2, 1–5 (2017). (PMID: 10.22270/ujpr.v2i2.RW1)
Mohamed, S. A. & Hargest, R. Surgical anatomy of the skin. Surg. Oxf. 40, 1–7 (2022).
Kok-Yong, S. & Lawrence, L. Drug distribution and drug elimination in basic pharmacokinetic concepts and some clinical applications. IntechOpen https://doi.org/10.5772/59929 (2015). (PMID: 10.5772/59929)
Ng, C. H. et al. Synthesis and docking studies of 2,4,6-trihydroxy-3-geranylacetophenone analogs as potential lipoxygenase inhibitor. Molecules 19, 11645–11659 (2014). (PMID: 25100256627141510.3390/molecules190811645)
Singh, I. P., Sidana, J., Bansal, P. & Foley, W. J. Phloroglucinol compounds of therapeutic interest: Global patent and technology status. Expert Opin. Ther. Pat. 19, 847–866 (2009). (PMID: 1947310510.1517/13543770902916614)
Shaari, K., Safri, S., Abas, F., Lajis, N. H. & Israf, D. A. A geranylacetophenone from the leaves of Melicope ptelefolia. Nat. Prod. Res. 20, 415–419 (2006). (PMID: 1664453810.1080/14786410500045655)
Antunes Viegas, D., Palmeira-de-Oliveira, A., Salgueiro, L., Martinez-de-Oliveira, J. & Palmeira-de-Oliveira, R. Helichrysum italicum: From traditional use to scientific data. J. Ethnopharmacol. 151, 54–65 (2014). (PMID: 2423984910.1016/j.jep.2013.11.005)
Sehra, S., Serezani, A. P. M., Ocaña, J. A., Travers, J. B. & Kaplan, M. H. Mast cells regulate epidermal barrier function and the development of allergic skin inflammation. J. Investig. Dermatol. 136, 1429–1437 (2016). (PMID: 2702140410.1016/j.jid.2016.03.019)
Stone, K. D., Prussin, C. & Metcalfe, D. D. IgE, mast cells, basophils, and eosinophils. J. Allergy Clin. Immunol. 125, S73–S80. https://doi.org/10.1016/j.jaci.2009.11.017 (2010). (PMID: 10.1016/j.jaci.2009.11.017201762692847274)
Oh, M., Zhu, Z., Yu, J. & Zheng, T. Role of mast cells in the development of atopic dermatitis induced by IL-13. J. Allergy Clin. Immunol. 129, AB36. https://doi.org/10.1016/j.jaci.2011.12.796 (2012). (PMID: 10.1016/j.jaci.2011.12.796)
Furue, M. et al. Pathogenesis of atopic dermatitis: Current paradigm. Iran. J. Immunol. 16, 97–107 (2019). (PMID: 31182684)
Renert-Yuval, Y. et al. Biomarkers in atopic dermatitis—A review on behalf of the International Eczema Council. J. Allergy Clin. Immunol. 147, 1174-1190.e1. https://doi.org/10.1016/j.jaci.2021.01.013 (2021). (PMID: 10.1016/j.jaci.2021.01.0133351687111304440)
Nakahara, T., Kido-Nakahara, M., Tsuji, G. & Furue, M. Basics and recent advances in the pathophysiology of atopic dermatitis. J. Dermatol. 48, 130–139 (2021). (PMID: 3311866210.1111/1346-8138.15664)
Ng, C. H. et al. Hits-to-lead optimization of the natural compound 2,4,6-trihydroxy-3-geranyl-acetophenone (tHGA) as a potent LOX inhibitor: Synthesis, structure-activity relationship (SAR) study, and computational assignment. Mol. J. Synth. Chem. Nat. Prod. Chem. 23, 2509 (2018).
Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27–31 (2016). (PMID: 27057123480440210.4103/0976-0105.177703)
Bos, J. D. & Meinardi, M. M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 9, 165–169 (2000). (PMID: 1083971310.1034/j.1600-0625.2000.009003165.x)
Herkenne, C. et al. In vivo methods for the assessment of topical drug bioavailability. Pharm. Res. 25, 87–103 (2008). (PMID: 1798521610.1007/s11095-007-9429-7)
Price, G. & Patel, D. A. Drug Bioavailability. http://www.ncbi.nlm.nih.gov/books/NBK557852/ (StatPearls Publishing, 2023).
Inagaki, N. & Nagai, H. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: Mouse models for the development of remedies for human allergic dermatitis. J. Pharmacol. Sci. 110, 251–259 (2009). (PMID: 1960906210.1254/jphs.09R01FM)
Mohd Kasim, V. N. K. et al. Management of atopic dermatitis via oral and topical administration of herbs in murine model: A systematic review. Front. Pharmacol. 13, 785782. https://doi.org/10.3389/fphar.2022.785782 (2022). (PMID: 10.3389/fphar.2022.785782356856369171034)
Martel, B. C., Lovato, P., Bäumer, W. & Olivry, T. Translational animal models of atopic dermatitis for preclinical studies. Yale J. Biol. Med. 90, 389–402 (2017). (PMID: 289551795612183)
Löwa, A., Jevtić, M., Gorreja, F. & Hedtrich, S. Alternatives to animal testing in basic and preclinical research of atopic dermatitis. Exp. Dermatol. 27, 476–483 (2018). (PMID: 2935609110.1111/exd.13498)
Wald, C. & Wu, C. Biomedical research. Of mice and women: The bias in animal models. Science 327, 1571–1572 (2010). (PMID: 2033904510.1126/science.327.5973.1571)
Barbarot, S. et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy 73, 1284–1293 (2018). (PMID: 2931918910.1111/all.13401)
Tuttle, K. L., Forman, J. & Beck, L. A. Novel systemic treatments in atopic dermatitis: Are there sex differences?. Int. J. Womens Dermatol. 7, 606–614 (2021). (PMID: 35024415872113010.1016/j.ijwd.2021.10.002)
Hon, K. L. et al. Age, sex, and disease status as determinants of skin hydration and transepidermal water loss among children with and without eczema. Hong Kong Med. J. 26, 19–26 (2020). (PMID: 32051333)
Mukai, K., Urai, T., Asano, K., Nakajima, Y. & Nakatani, T. Evaluation of effects of topical estradiol benzoate application on cutaneous wound healing in ovariectomized female mice. PLoS One 11, e0163560. https://doi.org/10.1371/journal.pone.0163560 (2016). (PMID: 10.1371/journal.pone.0163560276582635033238)
Kao, J. S. et al. Testosterone perturbs epidermal permeability barrier homeostasis. J. Investig. Dermatol. 116, 443–451 (2001). (PMID: 1123131910.1046/j.1523-1747.2001.01281.x)

UPM/800-3/3/1/GPB/9657600 Universiti Putra Malaysia

Keywords: Atopic dermatitis; Epidermal thickness; Mast cells; SCORAD; Th2 cytokines; tHGA

0 (Dinitrochlorobenzene)
37341-29-0 (Immunoglobulin E)
0 (Acetophenones)
207137-56-2 (Interleukin-4)

Date Created: 20240731 Date Completed: 20240731 Latest Revision: 20241001

20250114

PMC11291929

10.1038/s41598-024-66601-0

39085287